1. Home
  2. CLNN vs ANIX Comparison

CLNN vs ANIX Comparison

Compare CLNN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clene Inc.

CLNN

Clene Inc.

HOLD

Current Price

$6.07

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.71

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLNN
ANIX
Founded
2012
1982
Country
United States
United States
Employees
79
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.7M
88.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CLNN
ANIX
Price
$6.07
$2.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$33.75
$8.67
AVG Volume (30 Days)
671.8K
94.4K
Earning Date
05-08-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
$17.64
N/A
Revenue Next Year
$19,516.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$2.44
52 Week High
$13.50
$5.46

Technical Indicators

Market Signals
Indicator
CLNN
ANIX
Relative Strength Index (RSI) 44.04 40.80
Support Level $5.56 $2.65
Resistance Level $6.92 $3.12
Average True Range (ATR) 0.53 0.12
MACD -0.10 -0.02
Stochastic Oscillator 14.69 20.51

Price Performance

Historical Comparison
CLNN
ANIX

About CLNN Clene Inc.

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: